All News

Article

#ACRbest Abstracts – Day 3

Jack Cush, MD Nov 14, 2023

Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)

Low dose #prednisone has (bad) brain effects. An argument to use steroid sparing drugs in #PMR ⁦@philseo⁩ ⁦@ACRheum⁩ ⁦@RheumNow⁩ #ACR23 THINK about steroid sparing Rx in ?all pts with #PMR #Great #debate https://t.co/usQJRNUN8B

Anterior uveitis incidence across different axSpA treatments Large review and meta-analysis on TNFi, IL-17i, JAKi Immunomodulatory therapy protective against uveitis flare Greatest in TNFi and JAKi @RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt

#Lupus #ACR23🦋 🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy 🔥Promising step towards future in revolutionizing Lupus T/t💡📑 💡Keeps efficacy of other vaccines intact! Follow this thread showcasing other imp findings #ACRambassador 1/2 https://t.co/aNFTmJiH0X

✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus: BEFORE stepping-up with biologics, ask the key questions: -Are you using proton-pump inhibitors (Drug-induced SCLE) -Can I see your sunscreen? -Can I see your hat? -Are you smoking? -Any HCQ blood levels? https://t.co/s73FqyjLOn

#CAR T cells #ACR23 🔥Back to back Sessions on one of the most avidly researched area in Rheum! 💡Check out these slides to understand: ☣️Toxicities and Limitations of CAR T therapy 🆕 Novel CAR designs ⚡️CAR cell sources ❓Research Questions to ponder! #ACRambassador https://t.co/6sOn4rjqY3

Toxicities and limitations of CAR therapy: the other side of its incredibly exciting, boundless potential @Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC

Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor. 46% flared Seropositive- OR 2.0 NO association with mortality -ICIs are safe to use in RA -Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA

Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China 20% met def’n- diff trajectories 37% flare 1/6 got damage in f/u Some tapered Rx How to identify safe to d/c Rx? 2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz

Are all ICI-IA irAEs the same? @cappelliMD @jhrheumatology presented lovely work: latent class analysis on her cohort data She found two phenotypes - one with more persistent symptoms, & potentially a start in stratifying irAE therapy going forward. #ACR23 ABST2513 @RheumNow https://t.co/roW00KwbVZ

Patella tendon characteristics with USG - thickness, cross sectional area and stiffness measures with shear wave elastography In pts with or without knee pain @rheumnow #ACR23 52 pts Pain didnt correralate with thick ess and cross sectional area but did correlate with stiffness https://t.co/q3ZPG1l2n2

Plenary Abs #2425: Pregnancies among vasculitis pts - higher frequency of spontaneous abortion and preterm delivery. Risk of maternal complications associated with vasculitis were observed to vary by vessel size and parity. #ACR23 https://t.co/qLcpNapcjg @rheumnow https://t.co/sk3dhySVfP

LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I

AutoAb and irAE?? Really only associated for thyroid dysfunction. For ICI-IA we need different bio markers #ACR23 https://t.co/Fc24y8TzJv

Congratulations to Mount Sinai medical student and mentee Celestine He, on being awarded a Rheumatology Research Foundation Medical Student Preceptorship Award. Very proud of you and your excellent work! 👏🏻👏🏻👏🏻 #ACR23 @celestinejhe @MSRheumatology @IcahnMountSinai https://t.co/F078eSnL9p

Our collaborative study on nirmatrelvir-ritonavir (Paxlovid) virologic rebound is out in @AnnalsofIM @DrJLi @zach_wallace_md -Paxlovid: 21% with rebound vs. 2% in untreated (OR 10) https://t.co/RRDxerGdBy

US adults with #gout had higher 10-year all-cause mortality rates than those without Premature mortality in gout ➡️Has not improved over time despite improved survival in the general population ➡️Worse among women ➡️Worse among Black individuals #ACR23 👉🏽https://t.co/NDCIhKfCNL https://t.co/uKCswHKU0n